172 related articles for article (PubMed ID: 30197583)
1. Repeated Transarterial Chemoembolization with Degradable Starch
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study.
Orlacchio A; Chegai F; Francioso S; Merolla S; Monti S; Angelico M; Tisone G; Mannelli L
Curr Med Imaging Rev; 2018 Aug; 14(4):637-645. PubMed ID: 30197583
[TBL] [Abstract][Full Text] [Related]
2. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
3. Trans-Arterial Chemoembolization with 50 μm Degradable Starch Microspheres Versus 300-500 μm Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes.
Yildiz I; Deniz S; Ozer A; Caliskan K
J Belg Soc Radiol; 2022; 106(1):10. PubMed ID: 35434518
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma.
Furuse J; Ishii H; Satake M; Onaya H; Nose H; Mikami S; Sakai H; Mera K; Maru Y; Yoshino M
Am J Clin Oncol; 2003 Apr; 26(2):159-64. PubMed ID: 12714888
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Minici R; Ammendola M; Manti F; Siciliano MA; Minici M; Komaei I; Currò G; Laganà D
Front Pharmacol; 2021; 12():634087. PubMed ID: 33897422
[TBL] [Abstract][Full Text] [Related]
8. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
9. Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis.
Murata S; Tajima H; Ichikawa K; Onozawa S; Wang J; Kumita S; Nomura K
Hepatogastroenterology; 2008; 55(84):1041-6. PubMed ID: 18705325
[TBL] [Abstract][Full Text] [Related]
10. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
Iezzi R; Pompili M; Rinninella E; Annicchiarico E; Garcovich M; Cerrito L; Ponziani F; De Gaetano A; Siciliano M; Basso M; Zocco MA; Rapaccini G; Posa A; Carchesio F; Biolato M; Giuliante F; Gasbarrini A; Manfredi R;
Eur Radiol; 2019 Mar; 29(3):1285-1292. PubMed ID: 30171360
[TBL] [Abstract][Full Text] [Related]
11. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization.
Orlacchio A; Chegai F; Merolla S; Francioso S; Giudice CD; Angelico M; Tisone G; Simonetti G
World J Hepatol; 2015 Jun; 7(12):1694-700. PubMed ID: 26140089
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ
BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization with degradable starch microspheres (DSM-TACE): an alternative option for advanced HCC patients? Preliminary results.
Iezzi R; Pompili M; Nestola M; Siciliano M; Annicchiarico E; Zocco MA; Rinninella E; Posa A; Antonuccio GE; Gasbarrini A; Bonomo L;
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(13):2872-7. PubMed ID: 27424988
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy.
Schicho A; Pereira PL; Haimerl M; Niessen C; Michalik K; Beyer LP; Stroszczynski C; Wiggermann P
Oncotarget; 2017 Sep; 8(42):72613-72620. PubMed ID: 29069813
[TBL] [Abstract][Full Text] [Related]
15. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
16. European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden.
Ludwig JM; Iezzi R; Theysohn JM; Albrecht T; Posa A; Gross A
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680272
[TBL] [Abstract][Full Text] [Related]
17. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
20. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
